Erytech Pharma (NASDAQ:ERYP)‘s stock had its “buy” rating reaffirmed by research analysts at Cowen in a report issued on Sunday, AnalystRatings.com reports.
ERYP has been the topic of several other research reports. Zacks Investment Research lowered Erytech Pharma from a “hold” rating to a “sell” rating in a report on Thursday, September 19th. ValuEngine upgraded Erytech Pharma from a “hold” rating to a “buy” rating in a report on Thursday, August 15th. Finally, JMP Securities reiterated a “market outperform” rating and issued a $13.00 price target on shares of Erytech Pharma in a report on Thursday, September 5th.
Erytech Pharma stock traded up $0.11 during trading hours on Friday, hitting $4.91. The stock had a trading volume of 3,500 shares, compared to its average volume of 842. The business’s 50 day simple moving average is $4.49 and its 200-day simple moving average is $5.99. The stock has a market cap of $86.11 million, a price-to-earnings ratio of 2.01 and a beta of 1.48. The company has a quick ratio of 5.90, a current ratio of 5.91 and a debt-to-equity ratio of 0.08. Erytech Pharma has a one year low of $3.95 and a one year high of $10.65.
About Erytech Pharma
ERYTECH Pharma SA, a biopharmaceutical company, develops therapies for severe forms of cancer and orphan diseases. It is developing a pipeline of product candidates targeting solid and liquid tumors for patients with high unmet medical needs. The company's lead product candidate is eryaspase, which is used for the treatment of severe solid tumors, including pancreatic cancer and in acute lymphoblastic leukemia.
Read More: Why is the price-sales ratio important?
Receive News & Ratings for Erytech Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Erytech Pharma and related companies with MarketBeat.com's FREE daily email newsletter.